N'-硝基-D-精氨酸 | 66036-77-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 精氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N'-硝基-D-精氨酸
• 中文别名: N-硝基-D-精氨酸；D-Arg(NO2)-OH
• 英文名称: Nω-nitro-D-arginine
• 英文别名: N^G-nitro-D-arginine；D-NNA；nitro-D-arginine；(R)-N5-[amino(nitroimino)methyl]-ornithine；(2R)-2-amino-5-[(N'-nitrocarbamimidoyl)amino]pentanoic acid
• CAS: 66036-77-9
• 化学式: C₆H₁₃N₅O₄
• mdl: MFCD00066013
• 分子量: 219.2
• InChiKey: MRAUNPAHJZDYCK-SCSAIBSYSA-N

物化性质

• 熔点：
  253-254 °C(Solv: water (7732-18-5))
• 沸点：
  422.3±55.0 °C(Predicted)
• 密度：
  1.65±0.1 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  160
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2925290090
• 包装等级：
  III
• 危险类别：
  4.1
• 危险性防范说明：
  P261,P210,P264,P280,P370+P378,P302+P352+P312
• 危险品运输编号：
  1325
• 危险性描述：
  H302+H312+H332,H315,H319,H228
• 储存条件：
  存放于阴凉干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-D-Arg(No2)-OH
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-D-Arg(No2)-OH
CAS number: 66036-77-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H13N5O4
Molecular weight: 219.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

用作化学试剂。

用途简介

暂无具体用途说明。

用途

用作化学试剂。

反应信息

• 作为反应物：
  描述：

  N'-硝基-D-精氨酸 生成 N2-[(苄氧基)羰基]-N5-(N-硝基甲脒基)鸟氨酸
  参考文献：
  名称：

  TAKAGI, XIROSI;YASIMA, DZIMEHJ

  摘要：

  DOI：
• 作为产物：
  描述：

  D-精氨酸盐酸盐 在 硫酸 、 三氧化硫 、 硝酸 、 二氧化氮 作用下， 生成 N'-硝基-D-精氨酸
  参考文献：
  名称：

  Gibian,H.; Schroeder,E., Justus Liebigs Annalen der Chemie, 1961, vol. 642, p. 145 - 162

  摘要：

  DOI：

文献信息

• Amino acid derivatives, pharmaceutical compositions containing these
  申请人：Karl Thomae GmbH

  公开号：US06114390A1

  公开（公告）日：2000-09-05

  NPY-antagonistic compounds of the formula ##STR1## Exemplary are: (A) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -bis(4-hydroxyphenyl)acetyl]-argininamide-trifluoracetate; (B) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis(4-chlorphenyl)acetyl]-argininamide-trifluoracetate; (C) (R)-N-[[4-Aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -(diphenylacetyl)-argininamide-trifluoracetate; (D) (R)-N.sup.2 -(Diphenylacetyl)-N-[[4-(ethoxycarbonylmethylamino-carbonylaminomethyl)phe nyl]methyl]-argininamide-trifluoroacetate; (E) (R,S)-N.sup.5 -(Aminoiminomethyl)-N.sup.2 -(diphenylacetyl)-N-[(4-hy-droxyphenyl)methyl]-N.sup.5 -methyl-ornithinamide-hydrochloride; (F) (R)-N-[[4-(Aminocarbonylmethyl)phenyl]methyl]-N.sup.2 -(diphenyl-acetyl)-argininamide-diacetate; (G) (R)-N.sup.2 -(Diphenylacetyl)-N-[[4-(ethylaminocarbonylamino-methyl)-phenyl]methyl]-ar gininamide-bis-(trifluoroacetate); and, (H) (R)-N.sup.2 -(Diphenylacetyl)-N-[[4-(ethoxycarbonylamino-carbonylaminomethyl)phenyl]me thyl]-argininamide-trifluoroacetate.

  以下是NPY-拮抗性化合物的化学式及其示例的中文翻译： (A) (R)-N-[[4-(氨基甲酰氨基甲基)苯基]甲基]-N²-双(4-羟基苯基)乙酰基]-精氨酰胺-三氟乙酸盐； (B) (R)-N-[[4-(氨基甲酰氨基甲基)苯基]甲基]-N²-[双(4-氯苯基)乙酰基]-精氨酰胺-三氟乙酸盐； (C) (R)-N-[[4-氨基甲酰氨基甲基)苯基]甲基]-N²-(二苯基乙酰基)-精氨酰胺-三氟乙酸盐； (D) (R)-N²-(二苯基乙酰基)-N-[[4-(乙氧羰基甲基氨基-甲酰氨基甲基)苯基]甲基]-精氨酰胺-三氟乙酸盐； (E) (R,S)-N⁵-(氨基亚氨基甲基)-N²-(二苯基乙酰基)-N-[(4-羟基苯基)甲基]-N⁵-甲基-鸟氨酸酰胺-盐酸盐； (F) (R)-N-[[4-(氨基甲酰甲基)苯基]甲基]-N²-(二苯基-乙酰基)-精氨酰胺-二乙酸盐； (G) (R)-N²-(二苯基乙酰基)-N-[[4-(乙基氨基甲酰氨基甲基)-苯基]甲基]-精氨酰胺-双-(三氟乙酸盐)； (H) (R)-N²-(二苯基乙酰基)-N-[[4-(乙氧羰基氨基-甲酰氨基甲基)苯基]甲基]-精氨酰胺-三氟乙酸盐。
• Solid-Phase Total Synthesis and Structure Proof of Callipeltin B
  作者：Ravi Krishnamoorthy、Leslie D. Vazquez-Serrano、Jeffrey A. Turk、Jennifer A. Kowalski、Alan G. Benson、Nneka T. Breaux、Mark A. Lipton

  DOI：10.1021/ja0666250

  日期：2006.12.1

  The cytotoxic, cyclic heptadepsipeptide, natural product callipeltin B was synthesized on a solid-phase support in 15% overall yield. Comparison of the 1H NMR spectra of three synthetic isomers with those of callipeltin B confirmed the configurational reassignment of its threonine residues as d-allothreonine and the assignment of the configuration of its beta-methoxytyrosine residue as (2R,3R).

  细胞毒性、环状七肽、天然产物 callipeltin B 在固相载体上合成，总产率为 15%。三种合成异构体的 1H NMR 谱与 callipeltin B 的 1H NMR 谱的比较证实其苏氨酸残基的构型重新分配为 d-别苏氨酸，并将其 β-甲氧基酪氨酸残基的构型分配为 (2R,3R)。
• [EN] AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM<br/>[FR] DERIVES D'ACIDES AMINES, COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES ET PROCEDES DE PREPARATION DE CEUX-CI
  申请人：DR. KARL THOMAE GMBH

  公开号：WO1997019911A1

  公开（公告）日：1997-06-05

  (EN) The invention relates to new amino acid derivatives of general formula (I), wherein B, T, Z, Y, V and n are defined as in claim 1, the tautomers, diastereomers and enantiomers thereof, the mixtures thereof and the salts thereof, particularly their physiologically acceptable salts with inorganic or organic acids or bases which have valuable pharmacological properties, particularly selective NPY-antagonist properties, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them.(FR) L'invention concerne des nouveaux dérivés d'acides aminés de la formule générale (I), dans laquelle B, T, Z, Y, V et n sont tels que définis dans la revendication 1. L'invention concerne également des tautomères, diastéréomères et énantiomères de ces dérivés et leurs mélanges, ainsi que des sels de ces dérivés, notamment des sels d'addition d'acides ou de bases inorganiques ou organiques, acceptables sur le plan physiologique. Ces dérivés possèdent des propriétés pharmacologiques précieuses, notamment des propriétés antagonistes du neuropeptide Y. On décrit encore des compositions pharmaceutiques contenant ces composés ainsi que l'utilisation et des procédés de préparation de celles-ci.

  本发明涉及一般式(I)的新型氨基酸衍生物，其中B、T、Z、Y、V和n如权利要求1所定义，其互变异构体、对映异构体和外消旋体，以及它们的混合物和盐，特别是它们的生理上可接受的无机或有机酸或碱盐，具有有价值的药理学特性，特别是选择性NPY-拮抗剂特性，还涉及含有这些化合物的制药组合物、它们的用途以及制备它们的过程。
• Identification of the First Low-Molecular-Weight Inhibitors of Matriptase-2
  作者：Mihiret Tekeste Sisay、Torsten Steinmetzer、Marit Stirnberg、Eva Maurer、Maya Hammami、Jürgen Bajorath、Michael Gütschow

  DOI：10.1021/jm100183e

  日期：2010.8.12

  As recently discovered, matriptase-2, a type II transmembrane serine protease, plays a crucial role in body iron homeostasis by down-regulating hepcidin expression, which results in increased iron levels. Thus, matriptase-2 represents a novel target for the development of enzyme inhibitors potentially useful for the treatment of systemic iron overload (hemochromatosis). A comparative three-dimensional model of the catalytic domain of matriptase-2 was generated and utilized for structure-based virtual screening in combination with similarity searching and knowledge-based compound design. Two N-protected dipeptide amides containing a 4-amidinobenzylamide as PI residue (compounds 1 and 3) were identified as the first small molecule inhibitors of matriptase-2 with K-i values of 170 and 460 nM, respectively. An inhibitor of the closely related protease matriptase (compound 2, K-i = 220 nM), with more than 50-fold selectivity over matriptase-2, was also identified.
• Synthesis of arginine-containing hydroxamate dipeptidomimetics
  作者：Jiwon Seo、Richard B. Silverman

  DOI：10.1016/j.tetlet.2006.03.190

  日期：2006.6

  The syntheses of arginine-containing hydroxamates using various peptide coupling methods are described. Fmoc-Arg(NO2)-Cl prepared at low temperature did not undergo intramolecular delta-lactam formation and effectively provided desired hydroxamates (8 and 10) in good yields. Fmoc and N-nitro protecting groups can be easily removed. Therefore, this report provides a facile synthesis of arginine-containing peptidomimetic compounds. (c) 2006 Elsevier Ltd. All rights reserved.